deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT01059929

Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)

A Double-blinded Randomized Controlled Trial of Dexmedetomidine Versus Propofol for Sedation in Mechanically Ventilated Medical Intensive Care Unit Patients.

Sponsor: Hospira, now a wholly owned subsidiary of Pfizer

Conditions Critical Illness Mechanical Ventilation
Interventions Dexmedetomidine Fentanyl Midazolam Physical and Occupational Therapy Propofol
Updated 10 times since 2017 Last updated: Jul 2, 2018 Started: Sep 30, 2009 Primary completion: Sep 30, 2015 Completion: Sep 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

drug and placebo unavailable

Other terminated trials from Hospira, now a wholly owned subsidiary of Pfizer

See all terminations from Hospira, now a wholly owned subsidiary of Pfizer

Other Critical Illness trials with similar outcome

Browse all Critical Illness trials

Listed as NCT01059929, this PHASE4 trial focuses on Critical Illness and Mechanical Ventilation and remains terminated or withdrawn. Sponsored by Hospira, now a wholly owned subsidiary of Pfizer, it has been updated 10 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~May 2017 · 3 months · monthly snapshotUnknown Status~May 2017 – ~Jun 2018 · 13 months · monthly snapshotUnknown Status~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotUnknown Status~Aug 2018 – ~Jan 2021 · 29 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 21 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE4

  5. Jan 2021 — Dec 2022 [monthly]

    Terminated PHASE4

▶ Show 5 earlier versions

  1. Aug 2018 — Jan 2021 [monthly]

    Terminated PHASE4

    Status: Unknown Status → Terminated

  2. Jun 2018 — Aug 2018 [monthly]

    Unknown Status PHASE4

  3. May 2017 — Jun 2018 [monthly]

    Unknown Status PHASE4

  4. Feb 2017 — May 2017 [monthly]

    Unknown Status PHASE4

  5. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE4

    First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hospira, now a wholly owned subsidiary of Pfizer
  • University of Chicago
Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations